ReviewCurrent molecular medicine2012
Targeting regulatory T cells in the treatment of type 1 diabetes mellitus.
Review in Current molecular medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 51 citations in OpenAlex.
- Supplementation of High-Strength Oral Probiotics Improves Immune Regulation and Preserves Beta Cells among Children with New-Onset Type 1 Diabetes Mellitus: A Randomised, Double-Blind Placebo Control Trial.Indian journal of pediatrics · 2025Trial
- Mediators of the Association Between Severity of Noncommunicable Diseases and Subjective Health-Related Quality of Life.Neuropsychopharmacology reports · 2025Article
- Mechanism of Action of OralVaccines · 2024Article
- Teplizumab in Type 1 Diabetes Mellitus: An Updated Review.TouchREVIEWS in endocrinology · 2023Review
- Anti-CD20 therapy ameliorates β cell function and rebalances Th17/Treg cells in NOD mice.Endocrine · 2022Article
- Clinical Translational Potentials of Stem Cell-Derived Extracellular Vesicles in Type 1 Diabetes.Frontiers in endocrinology · 2021Review
- Could IL-17A Be a Novel Therapeutic Target in Diabetic Nephropathy?Journal of clinical medicine · 2020Review
- Potential Role of Gene Regulator NFAT5 in the Pathogenesis of Diabetes Mellitus.Journal of diabetes research · 2020Review
- Cellular immunological changes in patients with LADA are a mixture of those seen in patients with type 1 and type 2 diabetes.Clinical and experimental immunology · 2019Article
- Genetic and functional data identifying Cd101 as a type 1 diabetes (T1D) susceptibility gene in nonobese diabetic (NOD) mice.PLoS genetics · 2019Article
- Restoring self-tolerance in autoimmune diseases by enhancing regulatory T-cells.Cellular immunology · 2019Review
- Current Status on Immunological Therapies for Type 1 Diabetes Mellitus.Current diabetes reports · 2019Review
- Metformin mitigates autoimmune insulitis by inhibiting Th1 and Th17 responses while promoting Treg production.American journal of translational research · 2019Article
- An Overview on Probiotics as an Alternative Strategy for Prevention and Treatment of Human Diseases.Iranian journal of pharmaceutical research : IJPR · 2019Review
- Role of NFAT5 in the Immune System and Pathogenesis of Autoimmune Diseases.Frontiers in immunology · 2019Review
- Dipeptidyl peptidase-4(DPP-4) inhibitors: promising new agents for autoimmune diabetes.Clinical and experimental medicine · 2018Review
- Review
- CISH promoter polymorphism effects on T cell cytokine receptor signaling and type 1 diabetes susceptibility.Molecular and cellular pediatrics · 2018Article
- Human Gingiva-Derived Mesenchymal Stem Cells Ameliorate Streptozoticin-induced T1DM in mice via Suppression of T effector cells and Up-regulating Treg Subsets.Scientific reports · 2017Article
- Impact of T-cell-specific Smad4 deficiency on the development of autoimmune diabetes in NOD mice.Immunology and cell biology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Type 1 diabetes mellitus (T1DM) is a T cell-mediated autoimmune disease resulting in islet β cell destruction, hypoinsulinemia, and severely altered glucose homeostasis. T1DM has classically been attributed to the pathogenic actions of auto-reactive effector T cells(Teffs) on the β cell. Recent literature now suggests that a failure of a second T cell subtype, known as regulatory T cells (Tregs), plays a critical role in the development of T1DM. During immune homeostasis, Tregs counterbalance the actions of autoreactive Teff cells, thereby participating in peripheral tolerance. An imbalance in the activity between Teff and Tregs may be crucial in the breakdown of peripheral tolerance, leading to the development of T1DM. In this review, we summarize our current understanding of Treg function in health and in T1DM, and examine the effect of experimental therapies for T1DM on Treg cell number and function in both mice and humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.